Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

University of Arkansas25 enrolled

Overview

The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.

This is a study on volunteers to determine effective dose of dexrazoxane in degrading Topoisomerase 2 b in human blood samples. Each participant will receive one dose of dexrazoxane. Blood samples will be collected to determine the time course and degradation of Topoisomerase 2b and Topoisomerase 2a

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Degradation of Top2b and Top2a in Human by Dexrazoxane Time Course and Degradation of Top2b in Human by Dexrazoxane Effects of Dexrazoxane on Healthy Human

Interventions

DexrazoxaneDRUG

One dose of dexrazoxane

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women, * Age 18-65, * Not pregnant, Not currently breast feeding * No current illness, Exclusion Criteria: * Pregnancy, currently breast feeding * Current illness, * History of cardiac, or renal disease

Locations (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Outcomes

Primary Outcomes

Participants With 95% Reduction in Topoisomerase 2 b From Baseline

Number of participants with 95% reduction in topoisomerase 2 b from baseline is reported in the Outcome Measure Data Table

Time frame: 8 hours after dexrazoxane administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.